- Home
- EHI vs ANTX Comparison
EHI vs ANTX Comparison
Compare EHI & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EHI | ANTX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.2M | 170.7M |
| IPO Year | 2003 | 2022 |
Fundamental Metrics
Financial Performance| Metric | EHI | ANTX |
|---|---|---|
| Price | $5.99 | $4.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 92.3K | ★ 383.9K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.80 | $1.00 |
| 52 Week High | $6.70 | $6.91 |
Technical Indicators
Market Signals| Indicator | EHI | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 44.46 |
| Support Level | $5.89 | $3.82 |
| Resistance Level | $6.05 | $5.21 |
| Average True Range (ATR) | 0.06 | 0.40 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 61.11 | 0.91 |
Price Performance
Historical ComparisonAbout EHI Western Asset Global High Income Fund Inc
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income and total return by investing in a world-wide portfolio of securities. The fund invests in various sectors such as Consumer Discretionary, Financials, Energy, Communication energy, Industrials, materials, and others.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.